ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

GENF Genflow Biosciences Plc

3.10
0.00 (0.00%)
14 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Genflow Biosciences Plc GENF London Ordinary Share
  Price Change Price Change % Share Price Last Trade
0.00 0.00% 3.10 07:31:08
Open Price Low Price High Price Close Price Previous Close
3.10 3.10 3.10 3.10 3.10
more quote information »
Industry Sector
PHARMACEUTICALS & BIOTECHNOLOGY

Genflow Biosciences GENF Dividends History

No dividends issued between 15 Jun 2014 and 15 Jun 2024

Top Dividend Posts

Top Posts
Posted at 11/6/2024 13:28 by moneymunch
Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

1,633 followers
56m

A recent Prevention article pointed to daily exercise and a diet high in fruits & vegetables as ways to increase your #lifespan.

These measures do offer moderate improvements, yet #biotech research promises a much more significant extension. Genflow Biosciences (LON:GENF) (OTCQB:GENFF) promising #SIRT6 research is an example of research conducted that could combat aging and its symptoms.

Coupled with our growing IP portfolio, it’s no wonder The Guardian named us a firm to watch in 2024!

Read the Prevention article to learn how to extend your #healthspan in the meantime:

#aging #healthspan #GENF
Posted at 05/6/2024 10:31 by moneymunch
Genflow Biosciences (LON:GENF) (OTCQB:GENFF)
1,623 followers

16h

Aging is not only a societal challenge but also an #economic one. As the number of Americans over the age of 65 rises, so do the costs associated with healthcare.

Genflow Biosciences (LON:GENF) (OTCQB:GENFF) is filled with committed researchers who are working to lighten aging's financial burden.

#GENF offers:
↗️ research focusing on #centenarian variant of the #SIRT6 gene
↗️ promising, innovative treatments for a variety of illnesses
↗️ scientific advisory board is filled with dedicated & committed researchers

Make sure to take a look at National Library of Medicines take on the economic implications of aging :

#aging #healthspan
Posted at 16/5/2024 15:37 by moneymunch
Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

1,606 followers
3h

The #biotech space has continued to out perform expectations. As the industry is teetering on another market rally, many companies have had exciting developments.

Regeneron, for one, has announced it successfully restored the hearing of two children experiencing otoferlin hearing loss.

Additionally, Genflow Biosciences (LON:GENF) (OTCQB:GENFF) has secured several significant grants, some of whose payment is expected imminently. These will help advance its #sarcopenia & #mRNA delivery research.

Learn about Genflow's exciting investment proposition:

#pharma #aging #GENF
Posted at 14/5/2024 20:38 by moneymunch
Genflow Biosciences (LON:GENF) (OTCQB:GENFF)
1,604 followers

8h

The #biotech space is cluttered with many companies claiming to be on the cutting edge, with little to back this up. Genflow Biosciences (LON:GENF) (OTCQB:GENFF), on the other hand, stands out in numerous ways.

Differentiating between the true innovators and the rest can be difficult. That's why we've created a new fact sheet summarizing our exciting research that aims to extend both human and canine #healthspan.

What sets #GENF apart:
✅ Long life IP, protecting our #SIRT6 cenenarian gene & gene delivery research
✅ Creating #NASH treatment to address untapped market of 35 million people
✅ Lead by experienced team with a background running public companies

Learn more about Genflow's exciting investment thesis:
Posted at 01/5/2024 19:19 by moneymunch
Interesting for Genflow to post the following on Linkedin a couple of hours after suspension. Gla -)

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)



1,594 followers
6h

Stay up-to-date with Genflow Biosciences (LON:GENF) (OTCQB:GENFF)!

Sign up for our latest updates and be the first to know about our groundbreaking advancements. Don't miss important news & exclusive insights - subscribe now:

#GENF #GENFF #biotech #genetherapy #aging
Posted at 25/4/2024 12:54 by moneymunch
Genflow Biosciences (LON:GENF) (OTCQB:GENFF)
1,585 followers

23m

🧬 Genflow Biosciences has an updated presentation! 🧬

To learn more about the cutting-edge #biotech research & studies currently underway, as well as Genflow Biosciences (LON:GENF) (OTCQB:GENFF)'s strong investment thesis, click here:

#SIRT6 #GENF #NASH #aging #healthspan
Posted at 24/4/2024 06:47 by moneymunch
Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

1,585 followers
18h

Safety paramount in the #biotech industry, and at Genflow Biosciences (LON:GENF) (OTCQB:GENFF), it's our top priority. We're proud to have developed patent-pending technology to enhance safety in our #SIRT6 studies.

It is this unwavering commitment to safety that has allowed us to advance a number of our studies to the pre-clinical/development stage, including treatments for diseases ranging Werner Syndrome to #NASH.

Learn more about Genflow's innovative studies & exciting investment thesis:

#GENF #aging #healthspan #NASH #genetherapy
Investors – Genflow Bioscience
Posted at 27/1/2024 08:49 by moneymunch
Updates

View organization page for Genflow Biosciences (LON:GENF) (OTCQB:GENFF)
Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

1,455 followers
20h

Genflow Biosciences (LON:GENF) (OTCQB:GENFF) is excited to announce the release of its Annual 2023 Year in Review. This past year, we have achieved significant progress in our primary research areas in Non-Alcoholic Steatohepatitis (NASH) and Werner Syndrome.

Alongside these achievements, we have also made considerable strides in fortifying our corporate structure, enhancing our financial stability, and expanding our market presence to North America.

Read it here:

#longevity #NASH #Werner #SIRT6 #ageing #Genflow #GENF
Posted at 13/6/2023 07:02 by moneymunch
RNS Number : 4646C
Genflow Biosciences PLC
13 June 2023




Genflow Biosciences Plc



("Genflow" or "the Company")



Anti-Ageing Company, Genflow Biosciences, Announces Listing on OTCQB Venture Market

in addition to its LSE Main Market Listing



Genflow has 3 Gene Therapies in Development Seeking to Treat NASH and Werner Syndrome



Genflow Biosciences Plc ("Genflow" or "the Company") is pleased to announce that, after a successful application process, its Ordinary Shares ("Ordinary Shares") begin trading on the OTCQB Venture Market in the United States ("US") today under the symbol GENFF. Genflow will continue to trade on the London Stock Exchange ("LSE") Main Market under the symbol GENF, and, importantly, the onboarding to this additional U.S. securities trading platform does not involve any capital raise. The new U.S. trading facility expands access to a broader pool of investors and enables investors in the United States to trade during U.S. trading hours and in U.S. dollars.



Eric Leire, CEO of Genflow, expressed his excitement about this significant achievement, stating, "We are thrilled to announce that Genflow Biosciences has been admitted to trading on the OTCQB Venture Market in the United States. This move not only expands our reach to a larger investor base and has the potential to enhance liquidity for our shares, but also reinforces our unwavering commitment to our primary listing on the prestigious London Stock Exchange."



Tamara Joseph, Chair of the Board, also expressed her enthusiasm on behalf of the Board of Directors, saying, "Genflow is developing gene therapies that could address an important source of many global illnesses: aging. As the Company moves into Phase I/II clinical trials to treat potentially the orphan condition Werner Syndrome, which causes premature aging, and NASH, a liver disease that affects an estimated 35 million people around the world, it is the right time to retain our London Stock Exchange listing while adding easier access for US investors."



Further information on Genflow's application and the OTCQB market is below:



As a Foreign Private Issuer, Genflow's admission to the OTC Markets is subject to meeting the requirements for OTCQB, which apply to international reporting companies. This includes fulfilling the criteria for exemption under the US Exchange Act Rule 12g3-2(b) from SEC reporting. The Rule 12g3-2(b) exemption includes the disclosure obligation to ensure that certain information made public or distributed under home market regulations is made publicly available on the Company's website or other electronic information delivery system in English. Thus, the Company will have no additional reporting obligations and incur minimal ongoing costs; admission to the OTC Markets is subject to meeting the requirements for OTCQB, which apply to international reporting companies.



This includes fulfilling the criteria for exemption under the US Exchange Act Rule 12g3-2(b) from SEC reporting. Under this exemption, the Company must ensure that information made public or distributed under its home market regulations is made available to the public on its website or another electronic information delivery system in English. Consequently, Genflow will have no additional reporting obligations and will incur minimal ongoing costs compared to traditional major exchanges.



As a verified market, the OTCQB offers transparent trading for companies that have met a minimum bid price test, are current in their financial reporting and have undergone an annual verification and management certification process.



The cross-trading facility is provided through OTC Markets Group Inc., located in New York. OTC Markets operates the world's largest electronic interdealer quotation system for US broker-dealers and offers multiple media channels to increase the visibility of OTC-listed companies. Online brokers such as Ameritrade, Fidelity Investments, Tradestation, Charles Schwab and E-trade all offer OTCQB trades. US investors can find real-time quotes, market information and access current company news and developments on a BSF page on the OTC Markets website at www.otcmarkets.com.



Genflow appointed the corporate securities law firm Galanopoulos & Company as its OTCQB Sponsor to support its onboarding to the OTCQB Venture Market.



Additional information about the OTCQB market can be found at: www.otcmarkets.com/learn/market-101



The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.
Posted at 06/6/2023 19:06 by stark industries
Here's why this UK BioTech stock could potentially be set to rise imminently

Today I’m going to tell you about a revolutionary biotech startup that I previously tipped when it was trading at 2p back in November.

A company I believe is set to explode and has the potential to rise significantly in the near term.

What justifies such a bold prediction?


This company may hold the keys to the cure for aging...

The name of the company is Genflow Biosciences and it trades under the ticker (GENF) on the London stock exchange.

Consider that the biotech market is expected to reach USD 2.44 trillion by 2028 and expand at a CAGR of 15.83% until then.*

The demand for longevity is limitless, and the first companies that succeed in supplying the disruptive technologies that unlock it will capture the lion’s share of those trillions.

But before I go any further, let me ask you something…

Have you heard of the freshly minted biotech mega-startup that received $3 billion in backing in a single day?

According to Forbes, Altos Labs likely holds the world record for financing of any start-up by an order of magnitude or more.

With reports of early investments from entrepreneurial juggernaut Jeff Bezos and renowned info-tech investor Yuri Milner, Altos Labs is a likely contender for a top spot in the race to reverse aging and revolutionize medicine.

But backing from big names isn’t the only ace up the sleeve of Altos Labs…

The company has built an executive dream team of industry experts and scientific luminaries.

Among those reported to be joining the ambitious roster is none other than the Nobel prize winner for the discovery of reprogramming.


What is reprogramming and why is it important you might ask?

Shinya Yamanaka won his Nobel prize for discovering how to transform ordinary adult skin cells into any cell in the human body.

Need a new liver? Tired of living with Parkinson’s? Want your eyesight back?

Yamanaka’s research is key to engineering the regenerative medicine that will one day be responsible for replacing and repairing damaged organs and tissues.

With a deluge of capital and a hot shot team to employ it efficiently, Altos Labs is poised to accomplish its mission statement, “to restore cell health and resilience to reverse disease, injury, and disabilities that occur throughout life.”


But what does all of this have to do with Genflow Biosciences potentially significant rise in value?

I’m going to tell you, but first, let’s get some background.

Genflow Biosciences is challenging the aging process with exclusive patents to the leading longevity technology from the University of Rochester (US).

Okay, but why should we expect such sudden exponential growth.

The answer lies in a 2013 paper published in a highly regarded journal entitled “The Hallmarks of Ageing”...

To put it simply, the paper outlines 9 hallmarks of aging that provide a framework for prolonging human life. This roadmap to longevity spawned numerous biotech companies that used it as a roadmap for their R&D.


But even the companies regarded as the cream-of-crop are at a disadvantage…

They tend to focus on a single hallmark of aging. To quote Eric Leire, the company’s chief executive, “You’ve only solved one-ninth of the problem with this approach.”

Genflow Biosciences takes a holistic approach by targeting 4 of the 9 hallmarks directly, in addition to 2 indirectly. They are able to do this by focusing on the SIRT6 gene. This gene’s over expression has proven to extend the lives of healthy mice, winning it the title of the “master regulator of aging”.

This novel research has allowed the company to capture alluring patents, which brings us back to Altos Labs…

If anyone wants this IP they would have to purchase the company at a significant premium to the current share price or enter a licensing agreement.

Altos Labs opened only last year, in January of 2022. We know that Altos Labs has the ambition and the means to become the leader in longevity tech, and Genflow Biosciences likely holds the keys to that ambition.

It stands to reason that Genflow Biosciences could become an attractive acquisition target for a mega-tech startup such as Altos Labs.

Markets are extremely sensitive to takeovers, and the mere rumour of a potential acquisition could result in a drastic increase in Genflow's significantly undervalued share price


News like this could pop at any second. Launching Genflow Biosciences into the spotlight at any time this year.

This is a highly competitive industry and players with deep pockets see Genflow Biosciences’ IP as their ticket to the top of the market. If it’s not Altos Labs, then surely there will be another.

That is why I am recommending readers take a close look at it right now.

The company is currently eyeing a listing in other markets and a US listing may be on the horizon.


If I were to bet on the next big biotech stock story, Genflow BioSciences would be it.






Altos Labs opened only last year, in January of 2022. We know that Altos Labs has the ambition and the means to become the leader in longevity tech, and Genflow Biosciences likely holds the keys to that ambition.

It stands to reason that Genflow Biosciences could become an attractive acquisition target for a mega-tech startup such as Altos Labs.

Markets are extremely sensitive to takeovers, and the mere rumour of a potential acquisition could result in a drastic increase in Genflow's significantly undervalued share price



I suggest you all read through the attached link.
Mind Blowing as to how low our MCap is compared to our U.S neighbours
Target was 16p upon IPO and now with all the latest positives and the announcement of the U.S listing......expecting the share price to go to a realistic Mcap
conservative X 10 Share Price from current position !!!

Your Recent History

Delayed Upgrade Clock